Melanoma News and Research

Latest Melanoma News and Research

Combination of two targeted therapies increases survival in advanced melanoma

Combination of two targeted therapies increases survival in advanced melanoma

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

Researchers find mutated gene responsible for cardiac angiosarcoma in two brothers

Arteries may be best source for detecting circulating tumor cells

Arteries may be best source for detecting circulating tumor cells

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Researchers show how a cell surface protein can mobilize immune cells to attack malignant tumors

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

SunSense UK’s nationwide tour highlights the dangers of intentional tanning

SunSense UK’s nationwide tour highlights the dangers of intentional tanning

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Researchers discover new strategy for attacking cancer cells

Researchers discover new strategy for attacking cancer cells

UVA researchers identify new strategy for attacking cancer cells

UVA researchers identify new strategy for attacking cancer cells

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Innovative vaccine therapy shows promise against glioblastoma brain tumors

ICU-related mortality may explain variations in cancer outcomes

ICU-related mortality may explain variations in cancer outcomes

UCSF researchers lead $10 million research project on pediatric cancer

UCSF researchers lead $10 million research project on pediatric cancer

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.